Holobiome has built the Microbiome Vault, a diverse collection of human gut bacteria, and performs target-directed screening to map how the microbiome influences health. The company uses large datasets from these screens to inform development of novel consumer products and drug candidates. Its initial focus is on the gut–brain axis, with a lead program that is a next‑generation probiotic targeting biology relevant to depression. Holobiome advances additional programs via partnerships with major consumer, food, and pharmaceutical partners in areas including stress and pain. The company was launched in 2018 and is headquartered in Boston. Holobiome has secured substantial non-dilutive funding (including NIH and TRISH grants) and recently closed an institutional seed round to support clinical advancement and platform expansion.

Total raised

$9M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2024